research use only
Cat.No.S7612
| Related Targets | EGFR VEGFR JAK PDGFR FGFR Src FLT FLT3 HER2 Bcr-Abl |
|---|---|
| Other HIF Inhibitors | PT2399 BAY 87-2243 KC7F2 Lificiguat (YC-1) IOX2 CAY10585 (LW 6) PT2385 Molidustat (BAY 85-3934) IDF-11774 MK-8617 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| TW03-EBV cells | Function assay | 10 μM | 24 h | suppress HIF-1α expression | 30479336 | |
| H460 | Function assay | 10 μM | reduced glucose uptake and lactate production rate | 30128035 | ||
| A549 | Function assay | 10 μM | reduced glucose uptake and lactate production rate | 30128035 | ||
| SMMC7721 | Function assay | 25 μM | 24 h | inhibits migration of SMMC7721 | 29495380 | |
| EC9706 | Function assay | 20 μM | PX-478 inhibited normoxic and hypoxia-induced HIF-1α expression as well as COX-2 and PD-L1 expression | 28560067 | ||
| EC109 | Function assay | 20 μM | PX-478 inhibited normoxic and hypoxia-induced HIF-1α expression as well as COX-2 and PD-L1 expression | 28560067 | ||
| Tca8113 | Function assay | 0, 5, and 25 μM | 24 h | reduces cellular autophagy | 26640316 | |
| PDAC cell lines | Function assay | 25 μM | 24 h | induced a translocation of HMGB1 from the nucleus to the cytoplasm | 25544770 | |
| PC3 | Function assay | 20 hr | IC50 for HIF-1α inhibition for PC3 cells under normoxic condition was 20-25 μmol/L | 18729192 | ||
| DU 145 | Function assay | 20 hr | IC50 for HIF-1α inhibition for the DU 145 cells was ~40-50 μmol/L | 18729192 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs under hypoxic condition by MTT assay, IC50 = 19.7 μM. | 28209257 | ||
| MCF7 | Function assay | 24 hrs | Inhibition of HIF-1alpha (unknown origin) transcriptional activity expressed in human MCF7 cells after 24 hrs under hypoxic condition by HRE luciferase reporter gene assay , IC50 = 20.2 μM. | 28209257 | ||
| MDA-MB-468 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-468 cells after 72 hrs under hypoxic condition by MTT assay, IC50 = 45.1 μM. | 28209257 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 79 mg/mL
(200.44 mM)
Water : 79 mg/mL Ethanol : 79 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 394.12 | Formula | C13H20Cl4N2O3 |
Storage (From the date of receipt) | 3 years -20°C powder (seal) |
|---|---|---|---|---|---|
| CAS No. | 685898-44-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=CC=C1CC(C(=O)O)N)[N+](CCCl)(CCCl)[O-].Cl.Cl | ||
| Targets/IC50/Ki |
HIF-1α
|
|---|---|
| In vitro |
PX-478 2HCl lowers HIF-1α protein levels and HIF-1 transactivation in hypoxia and in normoxia in a variety of cancer cell lines, but has a more pronounced effect on translation of proteins, such as HIF-1α in hypoxia. This compound also enhances the radiosensitivity of prostate carcinoma PC3 cells. |
| In vivo |
In HT-29 human colon cancer xenografts, PX-478 2HCl suppresses HIF-1alpha levels and inhibits the expression of HIF-1 target genes including vascular endothelial growth factor and the glucose transporter-1. In addition, this compound (100 or 120 mg/kg i.p.) also shows antitumor activity including cures against several established human tumor xenografts that is related to the levels of HIF-1α. In high-fat-diet mice, this chemical causes reduced fibrosis and fewer inflammatory infiltrates in their adipose tissues. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | HIF-1α VEGF / Angiopoietin 1 E-cadherin / N-cadherin / Vimentin HIF-1α VEGF / Angiopoietin 1 E-cadherin / N-cadherin / Vimentin |
|
18729192 |
| Growth inhibition assay | Cell viability Cell viability |
|
28052321 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00522652 | Completed | Advanced Solid Tumors|Lymphoma |
Cascadian Therapeutics Inc.|Seagen Inc. |
August 2007 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.